Receptor interacting protein 3 protects mice from high-fat diet-induced liver injury

Hepatology

Volumn 64, Issue 5, 2016, Pages 1518-1533

  Roychowdhury, Sanjoy ^a,c   McCullough, Rebecca L ^a   Sanz Garcia, Carlos ^a   Saikia, Paramananda ^a   Alkhouri, Naim ^a   Matloob, Ammar ^a   Pollard, Katherine A ^a   McMullen, Megan R ^a   Croniger, Colleen M ^b   Nagy, Laura E ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CATHEPSIN B; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA1; COLLAGENASE 3; CYTOKERATIN 18; GLUCOSE; INSULIN; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; NECROSTATIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PALMITIC ACID; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN; RECEPTOR INTERACTING PROTEIN 3; SMALL INTERFERING RNA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE EXACERBATION; ENERGY EXPENDITURE; ENZYME ACTIVITY; FATTY ACID METABOLISM; FATTY LIVER; FEMALE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIPOTOXICITY; LIVER CELL; LIVER INJURY; MALE; MOUSE; NECROPTOSIS; NECROSIS; NONHUMAN; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY; RANDOMIZATION;

ANIMALS; APOPTOSIS; CELL DEATH; DIET, HIGH-FAT; HEPATOCYTES; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOM ALLOCATION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES;

EID: 84978779798     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28676     Document Type: Article

References (34)

1. Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 2011;35:445–455.
2. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014;147:765–783.
3. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005;54:1024–1033.
4. Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH, et al. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 2009;49:627–636.
5. Weber A, Boger R, Vick B, Urbanik T, Haybaeck J, Zoller S, et al. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010;51:1226–1236.
6. Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 2011;5:201–212.
7. Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 2010;53:542–550.
8. Wu W, Liu P, Li J. Necroptosis: an emerging form of programmed cell death. Crit Rev Oncol Hematol 2012;82:249–258.
9. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009;325:332–336.
10. Han J, Zhong CQ, Zhang DW. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol 2011;12:1143–1149.
11. Zhou W, Yuan J. Necroptosis in health and diseases. Semin Cell Dev Biol 2014;35:14–23.
12. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014;370:455–465.
13. Khan N, Lawlor KE, Murphy JM, Vince JE. More to life than death: molecular determinants of necroptotic and non-necroptotic RIP3 kinase signaling. Curr Opin Immunol 2014;26:76–89.
14. Ramachandran A, McGill MR, Xie Y, Ni HM, Ding WX, Jaeschke H. Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice. Hepatology 2013;58:2099–2108.
15. Roychowdhury S, McMullen MR, Pisano SG, Liu X, Nagy LE. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 2013;57:1773–1783.
16. Afonso MB, Rodrigues PM, Carvalho T, Caridade M, Borralho P, Cortez-Pinto H, et al. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin Sci (Lond) 2015;129:721–739.
17. Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C, et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 2014;6:1062–1074.
18. Kohli R, Feldstein AE. NASH animal models: are we there yet? J Hepatol 2011;55:941–943.
19. Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-kappaBs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol 2004;24:1464–1469.
20. Cohen JI, Roychowdhury S, McMullen MR, Stavitsky AB, Nagy LE. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology 139:664–674.
21. 4-induced fibrosis but not steatosis or inflammation. Alcohol Clin Exp Res 2012;36:1139–1147.
22. Gautheron J, Vucur M, Luedde T. Necroptosis in NASH. Cell Mol Gastroenterol Hepatol 2015;1:264–265.
23. Han W, Xie J, Li L, Liu Z, Hu X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 2009;14:674–686.
24. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015;517:311–320.
25. Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014;56:481–495.
26. Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 2013;108:1526–1531.
27. Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, Agboola KM, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009;50:1421–1430.
28. Galluzzi L, Vanden Berghe T, Vanlangenakker N, Buettner S, Eisenberg T, Vandenabeele P, et al. Programmed necrosis from molecules to health and disease. Int Rev Cell Mol Biol 2011;289:1–35.
29. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 2010;22:263–268.
30. Li Q, Li G, Lan X, Zheng M, Chen KH, Cao CM, et al. Receptor interacting protein 3 suppresses vascular smooth muscle cell growth by inhibition of the phosphoinositide 3-kinase-Akt axis. J Biol Chem 2010;285:9535–9544.
31. Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol 2015;1:17–27.
32. Liedtke C, Bangen JM, Freimuth J, Beraza N, Lambertz D, Cubero FJ, et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 2011;141:2176–2187.
33. Vucur M, Reisinger F, Gautheron J, Janssen J, Roderburg C, Cardenas DV, et al. RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. Cell Rep 2013;4:776–790.
34. Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012;55:419–428.